Status: Recruiting
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).
Participants needed: 520
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Axsome Therapeutics, Inc.Updated: Nov 25, 2025Locations: 40
Eligibility criteria
Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) cr... [+2]
Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescr... [+2]